Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist - PubMed (original) (raw)
. 2006 Dec 15;552(1-3):36-45.
doi: 10.1016/j.ejphar.2006.08.063. Epub 2006 Sep 14.
Affiliations
- PMID: 17056032
- DOI: 10.1016/j.ejphar.2006.08.063
Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist
Julia N Heinrich et al. Eur J Pharmacol. 2006.
Abstract
The pharmacology of aplindore (DAB-452) was characterized in CHO-K1 cells stably transfected with the human dopamine D(2) receptor short isoform (CHO-D(2s)) and in a behavioral model for post-synaptic agonism in rats. In [(3)H]-spiperone competition binding studies, aplindore showed high affinity for dopamine D(2) and D(3) receptors and low affinity for the dopamine D(4), serotonin (5-HT)(1A), 5-HT(2) receptors and the alpha1-adrenoceptor. The high potency partial agonist activity of aplindore was demonstrated in [(35)S]guanosine 5'-O-(3-thiotriphosphate) ([(35)S]GTPgammaS) binding, extracellular signal-regulated kinase (ERK)-phosphorylation and intracellular calcium flux assay using fluorometric plate reader ([Ca(2+)](i)-FLIPR) format. The [Ca(2+)](i)-FLIPR assay was conducted with CHO-D(2S) receptor cells also stably expressing chimeric G(alphaq/o)-proteins. In all assay modalities, the potencies and intrinsic activities of aplindore were lower than dopamine and higher than aripiprazole. In contrast to the [(35)S]GTPgammaS binding and ERK-phosphorylation assays, the [Ca(2+)](i)-FLIPR assay was able to detect the low partial agonist activity of SDZ 208-912. In unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats, aplindore induced contralateral turning, which was blocked by the dopamine D(2) receptor antagonist raclopride. The dopamine D(2) receptor selective partial agonist profile of aplindore suggests that it should be effective for the treatment of dopaminergic-based disorders, such as schizophrenia and Parkinson's disease.
Similar articles
- In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC. Glennon JC, et al. Synapse. 2006 Dec 15;60(8):599-608. doi: 10.1002/syn.20330. Synapse. 2006. PMID: 17001660 - S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ, Cussac D, Gobert A, Lejeune F, Rivet JM, Mannoury La Cour C, Newman-Tancredi A, Peglion JL. Millan MJ, et al. J Pharmacol Exp Ther. 2004 Jun;309(3):903-20. doi: 10.1124/jpet.103.062398. Epub 2004 Feb 20. J Pharmacol Exp Ther. 2004. PMID: 14978194 - Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
Jordan S, Johnson JL, Regardie K, Chen R, Koprivica V, Tadori Y, Kambayashi J, Kitagawa H, Kikuchi T. Jordan S, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):348-56. doi: 10.1016/j.pnpbp.2006.09.007. Epub 2006 Oct 27. Prog Neuropsychopharmacol Biol Psychiatry. 2007. PMID: 17070976 - Agonism and inverse agonism at dopamine D2-like receptors.
Strange PG. Strange PG. Clin Exp Pharmacol Physiol Suppl. 1999 Apr;26:S3-9. Clin Exp Pharmacol Physiol Suppl. 1999. PMID: 10386247 Review. - Agonist interactions with dopamine receptors: focus on radioligand-binding studies.
Creese I, Sibley DR, Leff SE. Creese I, et al. Fed Proc. 1984 Oct;43(13):2779-84. Fed Proc. 1984. PMID: 6383871 Review.
Cited by
- Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.
de Bartolomeis A, Tomasetti C, Iasevoli F. de Bartolomeis A, et al. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3. CNS Drugs. 2015. PMID: 26346901 Free PMC article. Review. - Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
Mailman RB, Murthy V. Mailman RB, et al. Curr Pharm Des. 2010;16(5):488-501. doi: 10.2174/138161210790361461. Curr Pharm Des. 2010. PMID: 19909227 Free PMC article. Review. - The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.
Jackson MJ, Andree TH, Hansard M, Hoffman DC, Hurtt MR, Kehne JH, Pitler TA, Smith LA, Stack G, Jenner P. Jackson MJ, et al. J Neural Transm (Vienna). 2010 Jan;117(1):55-67. doi: 10.1007/s00702-009-0323-9. Epub 2009 Oct 7. J Neural Transm (Vienna). 2010. PMID: 19809864 - Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous